Search
Forte Biosciences Inc
FBRXAdd to Watchlist
20.920USD
-0.400-1.88%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
270.88MMarket Cap
LossP/E TTM
More Details of Forte Biosciences Inc Company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc Info
Ticker SymbolFBRX
Company nameForte Biosciences Inc
IPO dateApr 13, 2017
CEOWagner (Paul A)
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 13
Address3060 Pegasus Park Drive
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75247
Phone13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
Ticker SymbolFBRX
IPO dateApr 13, 2017
CEOWagner (Paul A)
Company Executives of Forte Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.33K
+1.37%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.98K
+0.91%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.33K
+1.37%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.98K
+0.91%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
FAQs
Who are the top five shareholders of Forte Biosciences Inc?
The top five shareholders of Forte Biosciences Inc are: Dr. Paul A. Wagner, Ph.D.
How many institutions hold shares of Forte Biosciences Inc (FBRX)?
As of 2026Q1, 108 institutions hold shares of Forte Biosciences Inc, with a combined market value of approximately 12.72M, accounting for 65.47% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 288877.00.